Balancing Efficacy and Safety With MS Disease-Modifying Therapies: Omar Al-Louzi, MD
The director of the Visual Outcomes Laboratory at Cedars Sinai talked about the current treatments used in MS and the risks associated with them at 2023 ACTRIMS Forum. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
“Year by year, we're seeing that we can not only provide treatments that are effective, but we can balance the safety profile of those treatments, putting our patients with MS at minimum risk.”
In recent years, there have been several therapies developed for
Although with the many therapies available, clinicians may still face the challenge of trying to figure out treatment optimization and effectively monitor patients to see where discrepancies might form. On example is how researchers identified genetic variants associated with an increased risk of
REFERENCES
1. Research links gene variants to medication-induced fatal brain infection. News release. Emerald Lake Safety LLC. December 14, 2022. Accessed March 16, 2023. https://www.prnewswire.com/news-releases/research-links-gene-variants-to-medication-induced-fatal-brain-infection-301700933.html
2. Hatchwell E, Smith EB, Jalilzadeh S, et al. Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies. Front. Neurol. Published online December 14, 2022. doi:10.3389/fneur.2022.1016377
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Related Articles
- Pathophysiology of Myasthenia Gravis
September 18th 2025